Projeto
Rede Colaborativa Brasil de Pesquisa
Clínica sobre Covid-19 e Covid longa

Integrante da Plataforma Clínica Global da OMS

Seminário Internacional Plataforma Clínica Global Covid-19 e Pós-Covid/ Organização Mundial da Saúde- OMS: Resultados da Pesquisa, Desafios e Lições Aprendidas

Brasília-DF, 05 de dezembro/22

OPAS 120 | SUS | MINISTÉRIO DA SAÚDE

Data elements

Ronaldo Silva

on behalf of WHO Global Clinical Platform

Snap of diff. platforms

data

Collection

Quality

Analysis



data Collection | Quality | Analysis



Key concepts:

- Hospitals digitalized patient's records
- Health systems standardized data systems
- Data linkage
- Data hub
- Physicians improved quality of clinical data in patient's records

data Collection | Quality | Analysis

	A	B	C	D	E	F	G	H	I
1	WHO Global Clinical Platform for COVID-19: Data Correction								
2	Country:	xxxxx							
3	Facility:	xxxx Hospital							
4	Record ID:	2125-1							
5	Participant ID:	xxxx-001							
6	Total Missing:	62							
7	Total Errors:	2							
8	Yellow highlighting indicates a missing response								
9	Red highlighting indicates a response error or response outside the expected range								

11	Form	Section	Label	Response Options	Current Response	Corrected Response	variabl	Missin	Error
12	Admission	Administration	Record ID:		2125-1		record_id		
13	Admission	Administration	Facility name:		Arundel Hospital		admsit	FALSE	
14	Admission	Administration	Country:		Zimbabwe		admcou	FALSE	
15	Admission	Administration	Participant ID:		20010-001		admpar	FALSE	
16	Admission	Administration	Date of admission at this facility		2022-01-01		adm14	FALSE	FALSE
17	Admission	Inclusion Criteria	Presence of signs and symptoms suggestive of COV	1, Yes | 2, No | 3, Unknown	1		admx202	FALSE	
18	Admission	Inclusion Criteria	Laboratory confirmation of COVID-19 (antigen test	1, Yes | 2, No | 3, Unknown	1		admx203	FALSE	
19	Admission	Inclusion Criteria	If positive, date of most recent test		2021-12-31		admx204	FALSE	
20	Admission	Demographics	Sex at Birth:	1, Male | 2, Female | 3, Intersex |	1		adm07	FALSE	
21	Admission	Demographics	Date of birth:		1960-11-28		adm08	FALSE	FALSE
22	Admission	Demographics	If date of birth is unknown, specify age:				adm09_1		FALSE
23	Admission	Demographics	If children < 5 yrs, specify age in months:				admx205		
24	Admission	Demographics	Health worker in contact with patients:	1, Yes | 2, No | 3, Unknown	1		adm10	FALSE	
25	Admission	Demographics	Currently pregnant?	1, Yes | 2, No | 3, Unknown	2		adm12	FALSE	
26	Admission	Demographics	If No, was she pregnant within 22-42 days from adm	1, Yes | 2, No | 3, Unknown	2		admx12a_	FALSE	
27	Admission	Demographics	If currently or recently pregnant within≤ 21 days, gestational age:				adm12s		
28	Admission	Vaccination for COVID	Did the patient receive a COVID-19 vaccine	1, Yes | 2, No | 3, Unknown	1		admx211	FALSE	
29	Admission	Vaccination for COVID	Source of information	1, Documented Evidence (Vaccine	1		admx216	FALSE	
30	Admission	Vaccination for COVID	If yes, number of doses received	1, 1 | 2, 2 | 3, 3 | 4, Unknown	2		admx212	FALSE	
31	Admission	Vaccination for COVID	Dose 1, specify	1, Pfizer | 2, Moderna | 3, Janssen	6		admx213	FALSE	
32	Admission	Vaccination for COVID	Date of the 1st dose				admx213_	TRUE	
33	Admission	Vaccination for COVID	Dose 2, specify	1, Pfizer | 2, Moderna | 3, Janssen	6		admx214	FALSE	
34	Admission	Vaccination for COVID	Date of the 2nd dose				admx214_	TRUE	
35	Admission	Vaccination for COVID	Dose 3, specify	1, Pfizer | 2, Moderna | 3, Janssen | 4, AZ | 5, Sinovac | 6, Sinopharm			admx215		
50	Admission	Vital Signs at hospital	Height:				adm25	TRUE	
51	Admission	Vital Signs at hospital	Weight:		82		adm26	FALSE	FALSE

data Collection | Quality | Analysis
current challenge

COVID-19 Variants of Concern

Was sequencing of SARS-CoV-2 performed? ☐Yes ☐No ☐Unknown

Is the patient infected with a variant of concern (VOC) ? ☐Yes ☐No ☐Unknown **If No VOC**, indicate variant: _____

If VOC is identified , indicate the variant: ☐ Alpha - B.1.1.7, designated Dec 2020; ☐ Beta - B.1.351, designated Dec 2020; ☐ Gamma - P.1, designated Jan 2021; ☐ Delta - B.1.617.2, designated May 2021; ☐ Omicron, B.1.1.529, designated Oct 2021; ☐ Other, specify:_____

If VOC is identified, select method used: ☐ Sequencing ☐Proxy marker.

Sequencing
freq. not available;
Alternative is to use time and variant predominancy as proxy (GSAID database)

	50%														90%							
Country	Alpha (start)	Alpha (end)	Beta (start)	Beta (end)	Gamma (start)	Gamma (end)	Lambda (start)	Lambda (end)	Mu (start)	Mu (end)	Delta (start)	Delta (end)	Omicron (start)	Omicron (end)	Alpha (start)	Alpha (end)	Gamma (start)	Gamma (end)	Delta (start)	Delta (end)	Omicron (start)	Omicron (end)
Argentina					05/05/2021	08/24/2021					09/24/2021	12/21/2021	12/22/2021								01/08/2022	
Bolivia					03/17/2021	08/20/2021					09/10/2021	12/19/2021	12/19/2021						10/31/2021	11/23/2021	01/09/2022	
Brazil					02/03/2021	08/12/2021					08/12/2021	12/22/2021	12/22/2021				04/01/2021	07/08/2021	09/13/2021	12/10/2021	01/02/2022	
Canada	04/03/2021	06/07/2021									06/24/2021	12/15/2021	12/15/2021						07/29/2021	12/03/2021	12/27/2021	
Chile					05/10/2021	08/11/2021					09/01/2021	12/19/2021	12/19/2021						10/02/2021	12/04/2021	01/03/2022	
Colombia									04/30/2021	09/04/2021	09/08/2021	12/17/2021	12/17/2021						10/30/2021	11/21/2021	01/07/2022	
Ecuador											08/23/2021	12/21/2021	12/22/2021						10/14/2021	11/29/2021	01/11/2022	
Mexico											07/01/2021	12/20/2021	12/20/2021						08/06/2021	12/02/2021	01/07/2022	
Paraguay					04/04/2021	08/03/2021					08/11/2021	12/25/2021	12/25/2021						10/31/2021	11/09/2021	01/27/2022	
Peru							02/17/2021	07/25/2021			09/05/2021	12/27/2021	12/27/2021						10/22/2021	12/11/2021	01/11/2022	
United States of America	04/06/2021	06/02/2021									06/18/2021	12/19/2021	12/19/2021						07/22/2021	12/06/2021	12/31/2021	
Uruguay					04/02/2021	08/02/2021					08/03/2021	12/19/2021	12/19/2021				06/02/2021	07/19/2021	08/14/2021	11/23/2021	01/14/2022	
Venezuela					02/18/2021	05/13/2021					09/06/2021	12/28/2021	12/30/2021								02/02/2022	

data Collection | Quality | Analysis
current challenge

COVID-19 Variants of Concern



																90%						
Country	Alpha (start)	Alpha (end)	Beta (start)	B												amma start)	Gamma (end)	Delta (start)	Delta (end)	Omicron (start)	Omicron (end)	
Argentina																				01/08/2022		
Bolivia																		10/31/2021	11/23/2021	01/09/2022		
Brazil																01/2021	07/08/2021	09/13/2021	12/10/2021	01/02/2022		
Canada	04/03/2021	06/07/2021																07/29/2021	12/03/2021	12/27/2021		
Chile																		10/02/2021	12/04/2021	01/03/2022		
Colombia																		10/30/2021	11/21/2021	01/07/2022		
Ecuador																		10/14/2021	11/29/2021	01/11/2022		
Mexico																		08/06/2021	12/02/2021	01/07/2022		
Paraguay																		10/31/2021	11/09/2021	01/27/2022		
Peru																		10/22/2021	12/11/2021	01/11/2022		
United States of America	04/06/2021	06/02/2021												06/18/2021	12/19/2021	12/19/2021		07/22/2021	12/06/2021	12/31/2021		
Uruguay						04/02/2021	08/02/2021							08/03/2021	12/19/2021	12/19/2021	06/02/2021	07/19/2021	08/14/2021	11/23/2021	01/14/2022	
Venezuela						02/18/2021	05/13/2021							09/06/2021	12/28/2021	12/30/2021					02/02/2022	

Post (long) COVID-19



https://www.who.int/tools/global-clinical-platform

Global Clinical Platform

The WHO Global Clinical Platform for COVID-19

The WHO Global Clinical Platform for monkeypox

The WHO Global Clinical Platform for severe acute hepatitis of unknown aetiology in children

Communicable diseases

Coronavirus disease (COVID-19)

Communicable diseases

Ebola virus disease

Communicable diseases

Hepatitis

Diseases and conditions

Mpox (monkeypox)

Ebola

- **Objective 1:** Description of clinical characteristics
- **Objective 2:** Systematic recording of clinical interventions delivered within the MEURI framework
- **Objective 3:** Exploration of the determinants of patient outcomes (final diagnoses, dead/alive/referred out/etc. Sequelae on discharge)

MEURI (monitored emergency use of unregistered and experimental interventions)

Mpox

- **Objective 1:** Description of clinical characteristics
- **Objective 2:** Systematic description of interventions either clinically proven or delivered within the MEURI framework: including data on adverse events
- **Objective 3:** To identify broad patterns of outcomes within the overall cohort, including severity, extent and time to resolution of lesions

MEURI (monitored emergency use of unregistered and experimental interventions)

Seminário Internacional Plataforma Clínica Global Covid-19 e Pós-Covid/ Organização Mundial da Saúde- OMS: Resultados da Pesquisa, Desafios e Lições Aprendidas